ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Gilead addiction drug goes to start-up

by Michael McCoy
February 27, 2017 | APPEARED IN VOLUME 95, ISSUE 9

Gilead Sciences has sold Amygdala Neurosciences the rights to GS-6637, a small-molecule ALDH2 inhibitor with the potential to treat behavior and substance addictions by preventing dopamine surges. Former executives of CV Therapeutics, which Gilead bought in 2009, formed Amygdala to acquire GS-6637. According to Amygdala, Gilead invented GS-6637 based on an initial series of inhibitors synthesized by CV. Amygdala says it plans to start Phase II clinical trials this year.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment